NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
Journal of Clinical Oncology · 20.02.2023 · 41 (6) · 1285-1295
DOI: 10.1200/jco.22.00164 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.02.2023. Verfasst von Christina I Tsien und 16 weiteren Autor:innen. Beteiligte Einrichtung: Johns Hopkins School of Medicine, Baltimore, MD. Hauptthemen laut MEDLINE: Glioblastoma, Re-Irradiation, Brain Neoplasms. Die Arbeit wurde bisher 210-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE To assess whether reirradiation (re-RT) and concurrent bevacizumab (BEV) improve overall survival (OS) and/or progression-free survival (PFS), compared with BEV alone in recurrent glioblastoma (GBM). The primary objective was OS, and secondary objectives included PFS, response rate, and treatment adverse events (AEs) including delayed CNS toxicities. METHODS NRG Oncology/RTOG1205 is a prospective, phase II, randomized trial of re-RT and BEV versus BEV alone. Stratification factors included age, resection, and Karnofsky performance status (KPS). Patients with recurrent GBM with imaging evidence of tumor progression ≥ 6 months from completion of prior chemo-RT were eligible. Patients were randomly assigned 1:1 to re-RT, 35 Gy in 10 fractions, with concurrent BEV IV 10 mg/kg once in every 2 weeks or BEV alone until progression. RESULTS From December 2012 to April 2016, 182 patients were randomly assigned, of whom 170 were eligible. Patient characteristics were well balanced between arms. The median follow-up for censored patients was 12.8 months. There was no improvement in OS for BEV + RT, hazard ratio, 0.98; 80% CI, 0.79 to 1.23; P = .46; the median survival time was 10.1 versus 9.7 months for BEV + RT versus BEV alone. The median PFS for BEV + RT was 7.1 versus 3.8 months for BEV, hazard ratio, 0.73; 95% CI, 0.53 to 1.0; P = .05. The 6-month PFS rate improved from 29.1% (95% CI, 19.1 to 39.1) for BEV to 54.3% (95% CI, 43.5 to 65.1) for BEV + RT, P = .001. Treatment was well tolerated. There were a 5% rate of acute grade 3+ treatment-related AEs and no delayed high-grade AEs. Most patients died of recurrent GBM. CONCLUSION To our knowledge, NRG Oncology/RTOG1205 is the first prospective, randomized multi-institutional study to evaluate the safety and efficacy of re-RT in recurrent GBM using modern RT techniques. Overall, re-RT was shown to be safe and well tolerated. BEV + RT demonstrated a clinically meaningful improvement in PFS, specifically the 6-month PFS rate but no difference in OS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Johns Hopkins School of Medicine, Baltimore, MD.
- NRG Oncology Statistics and Data Management Center, Philadelphia, PA.
- Thomas Jefferson University, Philadelphia, PA.
- Northwestern University, Chicago, IL.
- University of Michigan, Ann Arbor, MI.
- Kaiser Permanente Sacramento Medical Center, Sacramento, CA.
ORCID-Profile: Christina I Tsien, Adam P Dicker, Jiayi Huang, John L Villano, Arif N Ali, Scott M Lindhorst, Minesh P Mehta
Förderung
- NCI NIH HHS
Zitieren
APA
Tsien, C. I., Pugh, S. L., Dicker, A. P., Raizer, J. J., Matuszak, M. M., Lallana, E. C., Huang, J., Algan, O., Deb, N., Portelance, L., Villano, J. L., Hamm, J. T., Oh, K. S., Ali, A. N., Kim, M. M., Lindhorst, S. M., & Mehta, M. P. (2023). NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma. Journal of Clinical Oncology, 41(6), 1285-1295. https://doi.org/10.1200/jco.22.00164
Vancouver
Tsien CI, Pugh SL, Dicker AP, Raizer JJ, Matuszak MM, Lallana EC, et al. NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma. Journal of Clinical Oncology. 2023;41(6):1285-1295. doi:10.1200/jco.22.00164
BibTeX
@article{Tsien2023,
author = {Tsien, Christina I and Pugh, Stephanie L and Dicker, Adam P and Raizer, Jeffrey J and Matuszak, Martha M and Lallana, Enrico C and Huang, Jiayi and Algan, Ozer and Deb, Nimisha and Portelance, Lorraine and Villano, John L and Hamm, John T and Oh, Kevin S and Ali, Arif N and Kim, Michelle M and Lindhorst, Scott M and Mehta, Minesh P},
title = {NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {6},
pages = {1285--1295},
doi = {10.1200/jco.22.00164}
}
EUVIMED